AstraZeneca
  • Bookmark This Page
  • Print This Page
  • Share with a Friend
Change Text Size
Change Text Size
Change Text Size
Change Text Size
Change Text Size

Guidelines for the management of asthma and related problems

Below is a list of links to the most recent guidelines for asthma management. While details may vary, guidelines emphasize an aggressive anti-inflammatory approach, regular physician follow-up, and attention to asthma triggers that are necessary to gain and maintain long-term control of persistent asthma.

Note: These Web sites are external to AstraZeneca. AstraZeneca does not possess editorial control of their content and no endorsement, expressed or implied, is intended.

Asthma guidelines

The Joint Task Force on Practice Parameters, Attaining optimal asthma control: a practice parameter, published in 2005 by a committee representing the AAAAI , ACAAI, and the JCAAI , builds upon the NAEPP report, and provides recommendations in the form of summary statements accompanied by grades of recommendations and levels of evidence.

The NAEPP Guideline, Expert Panel Report: guidelines for the diagnosis and management of asthma. Update on selected topics, last updated 2007. was developed in conjunction with the NIH through the NHLBI in response to the growing numbers of children with asthma. These practical guidelines promote optimal management of pediatric asthma and emphasize the safety and importance of long–term prevention and address, among other things, important accruing scientific data about inhaled corticosteroids therapy in children.

The AAAAI Guideline, American Academy of Allergy, Asthma and Immunology (AAAAI), in partnership with the American Academy of Pediatrics (AAP) and the National Asthma Education and Prevention Program (NAEPP), coordinated by the National Heart, Lung and Blood Institute, developed a comprehensive resource - Pediatric Asthma: Promoting Best Practice - a guide for managing asthma in children. This guide echoes the NAEPP; it stresses 4 key components to successful asthma management: 1) assessment and monitoring, 2) controlling aggravating factors, 3) pharmacologic treatment, and 4) patient education.

The Global Initiative for Asthma (GINA) Guideline, Pocket Guide for Asthma Management and Prevention in Children is a free, downloadable quick-reference guide for physicians and nurses who treat asthma in younger patients.

Related topics:

The ARIA Workshop Group’s Guideline, Allergic rhinitis and its impact on asthma helps providers recognize and manage the contribution of allergic rhinitis on asthma

The AAAAI Guideline, Allergen immunotherapy: a practice parameter reviews the potential benefits and administration of immunotherapy for children with allergic asthma.

The ACCP’s Guideline, Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines outlines the diagnosis and management of patients with cough-variant asthma.

The ACCP/ACAAI Guideline, Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology guides clinicians on the appropriate selection of an aerosol medication delivery device for asthmatic patients.

Abbreviations

AAAAI—American Academy of Allergy, Asthma and Immunology
ACAAI—American College of Allergy, Asthma and Immunology
JCAAI—Joint Council of Allergy, Asthma and Immunology
NAEPP—National Asthma Education and Prevention Program
NHLBI—National Heart, Lung, and Blood Institute
NIH—National Institutes of Health
WHO—World Health Organization
ARIA—Allergic Rhinitis and its Impact on Asthma
ACCP—American College of Chest Physicians
“Next” Button

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information (PDF).]